Children are therapeutic orphans and an underprivileged group in innovations derived from drug therapy. As the innovation process of pharmaceuticals is a long, risky and very costly business, economists typically emphasise lack of profit incentives and small market size as the most important...

Dean Baker and Adriane Fugh-Berman have published a critique of a study I performed in 2007, entitled Why has longevity increased more in some states than in others?" One of the conclusions I drew from that study was that medical innovation accounts for a substantial portion of recent increases...

As the innovation process of pharmaceuticals is a long, risky and very costly business, economists typically emphasise lack of profit incentives and small market size as the most important obstacles to child-related innovative activity. Moreover, there are ethical concerns because children are...

The objective of this paper is to analyse the dynamics of networks in which new knowledge emerges and through which it is exchanged. Our conjecture is that the structure of a network cannot be divorced from the dynamics of the knowledge underpinning its activities. In so doing we look beyond...

We study the impact a redistribution of income has on the decisions of a health care innovator and the utility of consumers. We find that income redistribution from rich to poor increases the quality of the medical innovation, reduces its price and increases the utility of some of the consumers...

This paper analyses the process of knowledge growth in a branch of medical science. Our study of scientific advances in glaucoma research is organized in two parts. In the first we present a qualitative overview of the problem sequences that have characterized 150 years of medical research in...